Close
CDMO Safety Testing 2026
Novotech

Schreiner MediPharm’s Pharma-Comb IL Label Supports Innovative Clinical Cancer Trial Utilizing Oncolytic Viruses

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

BeOne Signs $2B Trispecific Antibody Deal with Huahui Health

BeOne Medicines has entered into a high-value agreement with...

Quantum Computing Enhancing Clinical Trial Design

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

Glass vs Polymer: Choosing the Right Material for Parenteral Packaging

In the pharmaceutical industry, material selection plays a critical...
- Advertisement -

Schreiner MediPharm, a Germany-based globalย provider of innovative functional label solutions for the healthcare industry, isย supplying its durable Pharma-Comb IL Label solution to a company whose clinical trialย cancer medication requires low-temperature storage and pre-administration thawing,ย making marking and documentation particularly challenging.

Various clinical trials are currently focused on investigating the systematic use ofย oncolytic viruses in cancer therapies. Shanghai Yuan Song Biotechnology is among theย companies engaged in this research. For its trial relating to innovative virotherapy,ย Schreiner MediPharm supplies the appropriate specialty label, complete with variousย integrated functions, that easily withstands temperatures of -20 till -70 degrees Celsius.

Virotherapy is an immunotherapy in which patients receive injections with oncolyticย viruses. The treatment employs viruses to infect tumor cells, selectively destroyingย malignant cells. At Yuan Song Biotechnology, the active pharmaceutical ingredientย (API) for its vial-filled virotherapy cancer treatment is especially sensitive, posingย labeling challenges. The sensitive API must be stored and transported at lowย temperatures, and is subsequently thawed into a liquid before being administered.

These temperature differences place high demands on the reliable adhesion of theย marking and documentation label attached to unit-dose vials.ย In addition, prior to administering the drug, healthcare staff must check if the medicationย is flawless and the liquid is clear. A transparent inspection window must be integratedย into the label for that purpose. The label also must provide adequate space forย important information, and contain two removable parts for documenting theย administration of the medication in the patient and hospital files for the clinical trial.

For Yuan Song Biotechnology, the temperature stability and multifunctional benefits ofย Schreiner MediPharmโ€™s customized Pharma-Comb IL Label enabled reliable and clearย product marking, from storage to transportation to dispensing. The two removableย documentation labels have tabs allowing easy and efficient peel-off and attachment toย patient files. Thanks to the transparent inspection window, the vial liquid can be reliablyย checked prior to being administered. Thus, the Pharma-Comb IL Label from Schreinerย MediPharm helps optimize clinical trial processes and supports patient safety.

Latest stories

Related stories

BeOne Signs $2B Trispecific Antibody Deal with Huahui Health

BeOne Medicines has entered into a high-value agreement with...

Quantum Computing Enhancing Clinical Trial Design

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

Glass vs Polymer: Choosing the Right Material for Parenteral Packaging

In the pharmaceutical industry, material selection plays a critical...

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป